-
Mashup Score: 1
The results of this study suggest that GPRC5D is an active target for immunotherapy in multiple myeloma. GPRC5D-targeted CAR T-cell therapy is a promising treatment modality for patients with relapsed or refractory multiple myeloma and deserves further testing.
Source: The Lancet HaematologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Literature discussing endemic and regionally limited infections in recipients of haematopoietic stem-cell transplantation (HSCT) outside western Europe and North America is scarce. This Worldwide Network for Blood and Marrow Transplantation (WBMT) article is part one of two papers aiming to provide guidance to transplantation centres around the globe regarding infection prevention and treatment,…
Source: The Lancet HaematologyCategories: Hematologists1, Latest HeadlinesTweet-
Endemic or regionally limited bacterial and viral infections in haematopoietic stem-cell transplantation recipients: a Worldwide Network for Blood and Marrow Transplantation (WBMT) Review https://t.co/Sl4RMLcJbc
-
-
Mashup Score: 0Nothing about us should be without us - 2 year(s) ago
I was diagnosed with paroxysmal nocturnal haemoglobinuria (PNH) in my homeland, New Zealand, in 1997 after 3 years of investigations. At the time, there was neither treatment nor another patient to meet. PNH is a life-threatening, non-malignant, ultra-rare disease with an incidence of 1·3 cases per million people and a global prevalence of 16 cases per million people. It occurs when blood cells…
Source: The Lancet HaematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
"We welcome a future where biosimilars will allow many of our fellow patients around the world with no access to treatment, a chance at a normal life expectancy." Patient Voice by @PigginMaria @PNHSupport @GlobalPnh https://t.co/518pKGXEZj
-
-
Mashup Score: 0
Sovleplenib was well tolerated, and the recommended phase 2 dose showed a promising durable response in patients with primary immune thrombocytopenia, which provides evidence for future investigations. A phase 3 trial is ongoing (NCT05029635) to confirm the efficacy and safety of sovleplenib in patients with primary immune thrombocytopenia.
Source: The Lancet HaematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
NEW: Phase 1b/2 trial testing spleen tyrosine kinase (Syk) inhibitor sovleplenib in patients with primary immune thrombocytopenia. Dose escalation was done and promising activity shown at the recommended phase 2 dose. https://t.co/rWd02ZZ0qN https://t.co/KjlS86BpXE
-
-
Mashup Score: 2
Primary immune thrombocytopenia is an autoimmune disease associated with a reduced peripheral blood platelet count and complex underlying pathophysiology. Since spleen tyrosine kinase (Syk) is crucial in Fcγ receptor-mediated platelet phagocytosis, it was postulated that inhibition of Syk could be used as a possible mechanism to ameliorate disease activity. Syk inhibitors target not only…
Source: The Lancet HaematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
“This phase 1b/2 study is an important and encouraging step forward and the findings are worth confirming in future studies of other patient populations.” Linked Comment by Maria Lozano: https://t.co/pVj9om6pps
-
-
Mashup Score: 0The Sickle Cell Guide—equity for patients - 2 year(s) ago
Moved, amazed, and outraged! This is a game changer for sickle cell warriors of all ages living with the condition, their families, and carers. The Sickle Cell Guide provides an encyclopaedic knowledge of sickle cell disease, making it an essential read for medical professionals—from students to well seasoned consultants, medical directors, and policy makers. It quietly and humbly sets a new bar…
Source: The Lancet HaematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📚 Book review: Elliott Parris reviews The Sickle Cell Guide by Kye Gbangbola @SickleCellUK #sicklecell #sicklecellawareness https://t.co/5l55PdOZaX
-
-
Mashup Score: 2Pleural fluid overload-associated large B-cell lymphoma with a formerly double-hit genotype - 2 year(s) ago
A 72-year-old woman with a 4-month history of idiopathic pericardial effusion presented with left-sided pleural effusion in October, 2021, at Hygeia private hospital (Athens, Greece). She was immunocompetent with an unremarkable medical history. Cytological examination of the lymphocytic exudate revealed monotonous, large cells with irregular nuclear shape, condensed chromatin, prominent…
Source: The Lancet HaematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Thank you for taking part! The correct answer was C, fluid overload-associated large B-cell lymphoma with dual MYC and BCL6 rearrangements. For more, read our latest clinical picture here: https://t.co/SX2Te4jbix
-
-
Mashup Score: 1
Literature discussing endemic and regionally limited infections in recipients of haematopoietic stem-cell transplantation (HSCT) outside western Europe and North America is scarce. This Worldwide Network for Blood and Marrow Transplantation (WBMT) article is part one of two papers aiming to provide guidance to transplantation centres around the globe regarding infection prevention and treatment,…
Source: The Lancet HaematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
NEW: Two papers by the #WBMT review endemic or regionally limited #infections in haematopoietic stem-cell transplantation recipients #bmtsm @aljurf100 1⃣ Viral and bacterial infections 🦠https://t.co/NUUyWmcEuU 2⃣ Fungal and parasitic infections🦟https://t.co/i8ZNhgiEtY
-
-
Mashup Score: 0
Multidrug chemotherapy has historically been the cornerstone of therapy for both children and adults with acute lymphocytic leukaemia. However, in the past decade, several novel immunotherapies have proven to be highly effective in the treatment of acute lymphocytic leukaemia, including the anti-CD22 antibody–drug conjugate inotuzumab ozogamicin, the CD3 × CD19 bispecific antibody blinatumomab,…
Source: The Lancet HaematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic #leukaemia: breaking with the traditions of the past #leusm NEW Viewpoint by @NicholasShortMD and @DrHKantarjian @MDAndersonNews https://t.co/gNWQDhiku6 https://t.co/jC3tYrYyK2
-
-
Mashup Score: 0Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study - 2 year(s) ago
Eprenetapopt and venetoclax with azacitidine had an acceptable safety profile and encouraging activity, supporting further frontline evaluation of this combination in the treatment of TP53-mutated acute myeloid leukaemia.
Source: The Lancet HaematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
New, in the issue: eprenetapopt and venetoclax with azacitidine was safe and had encouraging activity in a phase 1 trial, supporting further frontline evaluation of this combination in patients with TP53-mutated acute myeloid leukaemia #leusm https://t.co/ftu25WAoaP https://t.co/zuiFt04kcT
-
GPRC5D CAR-T cells (OriCAR-017) in RRMM (POLARIS), Phase I trial. N=10, 5 with prior anti-BCMA CAR-T. CRS: 100%, NT: zero. ORR: 100% (sCR 60%, VGPR 40%) #mmsm #bmtsm #CARTcell https://t.co/5h58FrDYlb